Umezawa, Ueda, Maeda and others1) isolated an antibiotic from the cultured liquid of a streptomyces which was assigned to a new species, Streptomyces kanamyceticus, and named this antibiotic kanamycin. This antibiotic is one of those discovered by their systematic screening studies for the antibiotics which are water-soluble, basic and have no delayed toxicity. They considered that water-soluble, basic and low toxic antibiotics without any delayed toxicity would be equally effective both in vitro and in vivo, especially against tubercle bacilli. Their consideration was based on examples such as streptomycin, fradiomycin and viomycin. Kanamycin was an antibiotic of this category, and inhibited growth of Gram negative and positive bacteria including nonpathogenic mycobacteria. As shown by Takeuchi and others2), it was low in acute and chronic toxicities to experimental animals including mice, rats, rabbits and dogs. They also examined the absorption the blood level, the distribution among various organs and the excretion of this antibiotic in rabbits. To our particular interest, it was also proved that kanamycin worked against a streptomycin-resistant variant of E. coli at the same concentration as that against the sensitive parent strain.
These informations were sufficient to stimulate us to an attempt examine whether or not this antibiotic is likewise effective against virulent tubercle bacilli in vitro and further experimental tuberculosis in mice. This paper describes the results on the effect of the antibiotic on virulent tubercle bacilli in vitro and in mice. The potency of kanamycin has been decided by Umezawa to be expressed by the weight of its free base. According to this definition, mcg or mg of kanamycin shown in this paper indicates the weight of kanamycin free base contained in the material used for experiments.
View full abstract